יחס חוב לטווח קצר להון עצמי: Chromocell Therapeutics (CHRO)

This price chart illustrates the financial standing of Chromocell Therapeutics (CHRO), where the indicator stands at 0.00. Management of this micro-cap company is developing non-opioid analgesics despite a limited budget. The business relies on the study of ion channels, building valuable intellectual capital for future licensing deals. The startup is currently focusing on preclinical research, planning to attract a strategic partner to commercialize its molecules.

This ratio assesses liquidity risk by comparing liabilities maturing within one year against equity, while the history of short-term debt relative to equity determines the company's reliance on quick loans, which is critical for Chromocell Therapeutics (CHRO), whose significant pricing power in the inelastic demand segment for non-opioid pain relief should ensure the stability of its financial structure.